SynAct Pharma - Timeline - Created with VisMe

SynAct Pharma - Stormsteg mot exit! Redeye

Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag. The nomination committee proposes that he is elected as Board Member of the company and that Uli Hacksell is elected new Chairman of the Board.

Uli hacksell action pharma

InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences Board of directors Dr. Wenche Rolfsen. Chairman of the board since 2011. Born: 1952. Other current assignments: Rolfsen is chairman of the board of BioArctic AB, as well as board member of Cinclus Pharma Holding AB, Swedish Match AB and Rolfsen Consulting AB (as of which she also is CEO). Rolfsen is partner in Serendipity Partners. Uli Hacksell Cyclocondensation of 2-(2-cyano-1,2-diphenylethyl)quinuclidin-3-one 1 in the presence of sulfuric acid gave an intramolecular phenylation instead of lactam formation.

Kristina Luthman Göteborgs universitet

first_initial ACADIA Pharmaceuticals Inc.'s Email Format, Percentage Uli Hacksell's profile photo search features and then immediately take action, leaving your comp 19 Mar 2014 Uli Hacksell at University of Gothenburg Ethan S Burstein at ACADIA Pharmaceutical Krista McFarland at ACADIA Pharmaceuticals Based on its mechanism of action, pimavanserin may have antidepressant activity. David Hubbard , Uli Hacksell, Krista McFarland.

PRESSMEDDELANDE - GlobeNewswire

aktiebolagslagen (2005:551)).

Yilmaz Mahshid has tendered his resignation for personal reasons.
Preem aktie avanza

Uli has invested enormous energy in shaping … Uli Hacksell is considered to be independent in relation to SynAct as well as its senior management and in relation to major shareholders.

Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. Uli Hacksell. Born: 1950 Title: Member of the Board since 2018..
Samford basketball

christina anderson obituary
geographic information systems for the social sciences
vilka kommuner har bostadsbrist
köp aktiebolag
import från kina

Shareholders of SynAct Pharma proposes Uli Hacksell as new

Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and bi Acadia Pharmaceuticals Inc said it redesigned an ongoing late-stage study on its experimental anti-psychotic drug for Parkinson's disease patients, and that it plans to conduct an identical study Which company executives are buying and selling shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock? View the most recent insider trading activity for ACAD stock at MarketBeat. De senaste artiklarna från BioStock » Enzymatica om minskad försäljning och planerad nyemission » BioStock Live med CombiGene » Abliva slutför fas Ia/b studie med KL1333 » BioStock’s article series on MDR and IVDR: Notified Bodies – potential bottleneck » Nyemission finansierar utvecklingen av CombiGenes projekt mot nya milstolpar Läs BioStocks nyhetsbrev för vecka 11 här. Idag 11 Mar 2015 Acadia Pharmaceuticals Inc. won't be seeking regulatory approval for nervous system disorders, said longtime Chief Executive Uli Hacksell 24 Apr 2015 class action lawsuit against ACADIA Pharmaceuticals Inc. (“ACADIA” Chief Executive Officer ("CEO") and director, Uli Hacksell ("Hacksell"). Uli Hacksell, Ph.D.

ThinkPad T15 Gen 2 15" Intel

SynAct Pharma, från idé till verklighet.

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir.